WA
NTLA icon

Wasatch Advisors’s Intellia Therapeutics NTLA Stock Holding History

Wasatch Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.16M Sell
127,649
-134,215
-51% -$1.88M 0.01% 201
2026
Q1 		$3.36M Sell
261,864
-51,821
-17% -$660K 0.02% 182
2025
Q4 		$2.82M Buy
+313,685
New +$4.32M 0.02% 203

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Wasatch Advisors's NTLA Position: Q2 2026 in Review

Wasatch Advisors reduced its Intellia Therapeutics (NTLA) stake by 51% in Q2 2026, selling an estimated $1.88M and leaving 127,649 shares worth $2.16M. The position accounts for 0.01% of the portfolio, ranked #201.

Wasatch Advisors first reported a position in NTLA in Q4 2025 and has held it in 3 quarters since. The position peaked at $3.36M in Q1 2026. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Wasatch Advisors held 127,649 shares of Intellia Therapeutics worth $2.16M as of Q2 2026.
  • Wasatch Advisors sold 134,215 Intellia Therapeutics shares in Q2 2026, an estimated $1.88M.
  • Intellia Therapeutics made up 0.01% of Wasatch Advisors's portfolio in Q2 2026, its #201 holding.
  • Wasatch Advisors first reported a position in Intellia Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Wasatch Advisors's Intellia Therapeutics position peaked at $3.36M in Q1 2026.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Wasatch Advisors's 13F filing for Q2 2026, filed 10 Jul 2026.